Mumin Kazim Yazici
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mumin Kazim Yazici has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Ayşe Elif Anil Yağcioğlu
Department of Psychiatry, Faculty of Medicine, Hacettepe University, Ankara, Türkiye
14 shared publications - Aygün Ertuğrul
Hacettepe University
7 shared publications Sevilay Karahan
Department of Biostatistics, Hacettepe University Faculty of Medicine, Ankara, Turkey
5 shared publications- Ahmet Alp Karakaşlı
Hitit University
3 shared publications Nurhayat Eni
Department of Psychiatry, Hacettepe University Faculty of Medicine, Sihhiye, Ankara, 06100, Turkey
3 shared publicationsA. Ertuğrul
Department of Psychiatry, Hacettepe University Faculty of Medicine, Ankara, Turkey
2 shared publications
Latest Publications
- 3 February 2023
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 43 (2) , 180-183
Hodgkin Lymphoma in Patients Receiving Clozapine Treatment
- 3 February 2023
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 43 (2) , 180-183
Hodgkin Lymphoma in Patients Receiving Clozapine Treatment
- Open Access
- 13 June 2022
- Published by Hacettepe University - Medical School in Acta Medica
Effects of the COVID-19 Pandemic on Patients with Schizophrenia Spectrum Disorders
Objective: To evaluate the mental health of patients with schizophrenia spectrum disorders with the prolongation of the pandemic. Materials and Methods: This descriptive cross-sectional study was conducted between August-October 2020. Fifty-two patients with schizophrenia spectrum disorders who were hospitalized prior to the onset of the pandemic between March 2019-March 2020 at the inpatient clinic were reassessed during the pandemic. The Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impression-Severity (CGI-S) Scale, Hamilton Depression Rating Scale (HAM-D), Hamilton Anxiety Rating Scale (HAM-A) and Fear of COVID-19 Scale were used to evaluate psychopathology during the pandemic. The PANSS and the CGI severity scores at discharge from the inpatient clinic for each patient were obtained from the medical records review for comparison along with sociodemographic variables. Results: A total of 34 patients, 33 with schizophrenia (97.1%) and 1 with schizoaffective disorder (2.9%) were included. There was no significant difference between the pre- and during the pandemic assessments in the PANSS total and the CGI severity scores. The PANSS total, the CGI, HAM-D, HAM-A and the Fear of COVID-19 scale scores, medical comorbidity and utilization of psychiatric health care services were significantly higher in patients who reported subjectively increased psychiatric symptoms during the pandemic. There was no significant difference in the change of PANSS total and CGI scores between the two groups. Fear of COVID-19 Scale and HAM-A scores were correlated positively. Conclusion: During pandemic increase in psychiatric symptoms may be related not only to psychosis but also depression, anxiety. According to the results of patients who reported subjectively increased psychiatric symptoms during the pandemic, while the psychotic symptoms did not worsen during the pandemic, patients with higher anxiety or depression scores reported an increase in their symptoms and were more likely to seek help.
- 13 June 2022
- Published by Hacettepe University - Medical School in Acta Medica
Open AccessEffects of the COVID-19 Pandemic on Patients with Schizophrenia Spectrum Disorders
Objective: To evaluate the mental health of patients with schizophrenia spectrum disorders with the prolongation of the pandemic. Materials and Methods: This descriptive cross-sectional study was conducted between August-October 2020. Fifty-two patients with schizophrenia spectrum disorders who were hospitalized prior to the onset of the pandemic between March 2019-March 2020 at the inpatient clinic were reassessed during the pandemic. The Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impression-Severity (CGI-S) Scale, Hamilton Depression Rating Scale (HAM-D), Hamilton Anxiety Rating Scale (HAM-A) and Fear of COVID-19 Scale were used to evaluate psychopathology during the pandemic. The PANSS and the CGI severity scores at discharge from the inpatient clinic for each patient were obtained from the medical records review for comparison along with sociodemographic variables. Results: A total of 34 patients, 33 with schizophrenia (97.1%) and 1 with schizoaffective disorder (2.9%) were included. There was no significant difference between the pre- and during the pandemic assessments in the PANSS total and the CGI severity scores. The PANSS total, the CGI, HAM-D, HAM-A and the Fear of COVID-19 scale scores, medical comorbidity and utilization of psychiatric health care services were significantly higher in patients who reported subjectively increased psychiatric symptoms during the pandemic. There was no significant difference in the change of PANSS total and CGI scores between the two groups. Fear of COVID-19 Scale and HAM-A scores were correlated positively. Conclusion: During pandemic increase in psychiatric symptoms may be related not only to psychosis but also depression, anxiety. According to the results of patients who reported subjectively increased psychiatric symptoms during the pandemic, while the psychotic symptoms did not worsen during the pandemic, patients with higher anxiety or depression scores reported an increase in their symptoms and were more likely to seek help.
- Open Access
- 1 January 2020
- Published by Turkish Association of Nervous and Mental Health in Turkish Journal of Psychiatry
- Vol. 31 (3) , 159-167
Effect of Clozapine on Proton Magnetic Resonance Spectroscopy Findings in Hippocampus
The purpose of this study was to investigate the effect of clozapine on proton magnetic resonance spectroscopy (1H-MRS) findings in hippocampus in patients with schizophrenia. In addition, the relationship between the change in 1H-MRS findings and the change in psychopathology and neurocognitive functions was evaluated. Patients with schizophrenia (n=16) were assessed with the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression Scale (CGI), a neurocognitive test battery and 1H-MRS at baseline, and twelve weeks after the initiation of clozapine. Healthy controls (n=8) were assessed once with a neurocognitive test battery and 1H-MRS. Bilateral multivoxel and left single voxel NAA/Cr, Cho/Cr, MI/Cr was calculated in the hippocampi. After 12 weeks of clozapine treatment, PANSS and CGI scores decreased; immediate recall, cumulative learning subtests of the Rey Auditory Verbal Learning Test, Category Verbal Fluency Test and Wechsler Memory Scale's visual reproduction delayed subtest scores increased significantly. Compared with healthy controls and patients after clozapine, hippocampi multivoxel and single voxel NAA/Cr, Cho/ Cr, MI/Cr ratios were not different in patients before clozapine. No significant correlations between change in 1H-MRS metabolite ratios and change in psychopathology, neurocognitive functions were detected. This study is the first longitudinal study to investigate the effect of clozapine in hippocampus with 1H-MRS. There were no significant changes in 1H-MRS findings in hippocampi after twelve weeks of clozapine treatment. Clozapine's effect in hippocampus should be investigated further in longer follow up studies with larger samples to reach a final conclusion.
- 1 January 2020
- Published by Turkish Association of Nervous and Mental Health in Turkish Journal of Psychiatry
- Vol. 31 (3) , 159-167
Open AccessEffect of Clozapine on Proton Magnetic Resonance Spectroscopy Findings in Hippocampus
The purpose of this study was to investigate the effect of clozapine on proton magnetic resonance spectroscopy (1H-MRS) findings in hippocampus in patients with schizophrenia. In addition, the relationship between the change in 1H-MRS findings and the change in psychopathology and neurocognitive functions was evaluated. Patients with schizophrenia (n=16) were assessed with the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression Scale (CGI), a neurocognitive test battery and 1H-MRS at baseline, and twelve weeks after the initiation of clozapine. Healthy controls (n=8) were assessed once with a neurocognitive test battery and 1H-MRS. Bilateral multivoxel and left single voxel NAA/Cr, Cho/Cr, MI/Cr was calculated in the hippocampi. After 12 weeks of clozapine treatment, PANSS and CGI scores decreased; immediate recall, cumulative learning subtests of the Rey Auditory Verbal Learning Test, Category Verbal Fluency Test and Wechsler Memory Scale's visual reproduction delayed subtest scores increased significantly. Compared with healthy controls and patients after clozapine, hippocampi multivoxel and single voxel NAA/Cr, Cho/ Cr, MI/Cr ratios were not different in patients before clozapine. No significant correlations between change in 1H-MRS metabolite ratios and change in psychopathology, neurocognitive functions were detected. This study is the first longitudinal study to investigate the effect of clozapine in hippocampus with 1H-MRS. There were no significant changes in 1H-MRS findings in hippocampi after twelve weeks of clozapine treatment. Clozapine's effect in hippocampus should be investigated further in longer follow up studies with larger samples to reach a final conclusion.
- 1 September 2019
- Published by Elsevier in Psychiatry Research
- Vol. 279, 90-97
A comparative study of detection of myocarditis induced by clozapine: With and without cardiac monitoring
- 1 September 2019
- Published by Elsevier in Psychiatry Research
- Vol. 279, 90-97
A comparative study of detection of myocarditis induced by clozapine: With and without cardiac monitoring
- Open Access
- 1 August 2019
- Published by Elsevier in Comprehensive Psychiatry
- Vol. 93, 7-13
Examination of formal thought disorder and its clinical correlates with the Turkish Version of the Thought and Language Disorder Scale (TALD-TR) in schizophrenia
- 1 August 2019
- Published by Elsevier in Comprehensive Psychiatry
- Vol. 93, 7-13
Open AccessExamination of formal thought disorder and its clinical correlates with the Turkish Version of the Thought and Language Disorder Scale (TALD-TR) in schizophrenia
- 27 April 2019
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 270 (5) , 611-618
A follow-up study of metabolic syndrome in schizophrenia
The prevalence of metabolic syndrome (MetS) in schizophrenia patients is increasing worldwide. The aim of the current study was to examine the progress of MetS in a schizophrenia cohort we had previously investigated and determine the role of various related factors, including sociodemographic and clinical variables, nutritional status and physical activity. Of the 319 patients investigated in the first study, 149 patients agreed to be included in the follow-up. Physical measurements and laboratory tests were performed in addition to evaluations with the Positive and Negative Syndrome Scale, Udvalg for Kliniske Undersogelser Side Effects Scale, International Physical Activity Questionnaire, 24 h dietary recall method and Nutrition Information Systems Package Program. According to the ATPIII, ATPIIIA and IDF criteria, the MetS prevalences had increased from 35.6 to 44.3%, 38.9 to 53% and 43.6 to 55.7%, respectively. Patients with MetS had a shorter period of hospitalization and a higher UKU total side effects score, and most of them were married or divorced/widowed. Patients with MetS also had a higher daily consumption of added sugar, cholesterol, polyunsaturated fatty acids and omega 3 fatty acid, and the daily added sugar intake was found to be related to the increase in MetS. Unexpectedly, the physical activity level was not found to significantly differ in the patients with and without MetS. In conclusion, the MetS prevalence was found to be increased among schizophrenia patients over time, and the increase in the young age group was particularly striking. Among all of the factors investigated, nutritional status was found to play a major role in this increased prevalence.
- 27 April 2019
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 270 (5) , 611-618
A follow-up study of metabolic syndrome in schizophrenia
The prevalence of metabolic syndrome (MetS) in schizophrenia patients is increasing worldwide. The aim of the current study was to examine the progress of MetS in a schizophrenia cohort we had previously investigated and determine the role of various related factors, including sociodemographic and clinical variables, nutritional status and physical activity. Of the 319 patients investigated in the first study, 149 patients agreed to be included in the follow-up. Physical measurements and laboratory tests were performed in addition to evaluations with the Positive and Negative Syndrome Scale, Udvalg for Kliniske Undersogelser Side Effects Scale, International Physical Activity Questionnaire, 24 h dietary recall method and Nutrition Information Systems Package Program. According to the ATPIII, ATPIIIA and IDF criteria, the MetS prevalences had increased from 35.6 to 44.3%, 38.9 to 53% and 43.6 to 55.7%, respectively. Patients with MetS had a shorter period of hospitalization and a higher UKU total side effects score, and most of them were married or divorced/widowed. Patients with MetS also had a higher daily consumption of added sugar, cholesterol, polyunsaturated fatty acids and omega 3 fatty acid, and the daily added sugar intake was found to be related to the increase in MetS. Unexpectedly, the physical activity level was not found to significantly differ in the patients with and without MetS. In conclusion, the MetS prevalence was found to be increased among schizophrenia patients over time, and the increase in the young age group was particularly striking. Among all of the factors investigated, nutritional status was found to play a major role in this increased prevalence.
- 1 September 2018
- Published by Turkish Association of Nervous and Mental Health in Turkish Journal of Psychiatry
- Vol. 29 (3) , 147-153
L-Arginine Add-On Treatment for Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study
Introduction: Current drug treatments for schizophrenia are only partially effective and combination/augmentation strategies are commonly used. Nitric Oxide (NO) may play a role in the pathophysiology of schizophrenia. L-arginine is the precursor of NO. In this study, we aimed to investigate whether L-arginine add-on to current medication might improve positive, negative, and depressive symptoms in schizophrenia/schizoaffective disorder patients in partial remission. Method: The study was designed as a randomized, double-blind, placebo-controlled, crossover study of L-arginine 3 g b.i.d. as an add-on treatment to the patients' usual medication. Twelve patients diagnosed with schizophrenia/schizoaffective disorder were included. The duration of the treatment was 3 weeks, with a wash-out period of 7 days before alternation for the second arm. Psychopathology was assessed with the Positive and Negative Syndrome Scale (PANSS), the Calgary Depression Scale for Schizophrenia (CDSS), and the Clinical Global Impression (CGI) scales. The study was supported by Hacettepe University Scientific Research and Development Office (Project No: 011D0110101013) (Clinical Trials.gov Identifier: NCT02398279) Results: Our analyses revealed that L-arginine 6 g/day add-on to usual treatment was not superior to placebo for positive, negative, and depressive symptoms associated with schizophrenia as assessed with PANSS, CDSS and CGI scales. Conclusion: In our study, L-arginine did not seem to have an effect on schizophrenia symptoms. Studies with a larger sample size, with higher doses of L-arginine, and with a longer duration are needed for a definite conclusion.
- 1 September 2018
- Published by Turkish Association of Nervous and Mental Health in Turkish Journal of Psychiatry
- Vol. 29 (3) , 147-153
L-Arginine Add-On Treatment for Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study
Introduction: Current drug treatments for schizophrenia are only partially effective and combination/augmentation strategies are commonly used. Nitric Oxide (NO) may play a role in the pathophysiology of schizophrenia. L-arginine is the precursor of NO. In this study, we aimed to investigate whether L-arginine add-on to current medication might improve positive, negative, and depressive symptoms in schizophrenia/schizoaffective disorder patients in partial remission. Method: The study was designed as a randomized, double-blind, placebo-controlled, crossover study of L-arginine 3 g b.i.d. as an add-on treatment to the patients' usual medication. Twelve patients diagnosed with schizophrenia/schizoaffective disorder were included. The duration of the treatment was 3 weeks, with a wash-out period of 7 days before alternation for the second arm. Psychopathology was assessed with the Positive and Negative Syndrome Scale (PANSS), the Calgary Depression Scale for Schizophrenia (CDSS), and the Clinical Global Impression (CGI) scales. The study was supported by Hacettepe University Scientific Research and Development Office (Project No: 011D0110101013) (Clinical Trials.gov Identifier: NCT02398279) Results: Our analyses revealed that L-arginine 6 g/day add-on to usual treatment was not superior to placebo for positive, negative, and depressive symptoms associated with schizophrenia as assessed with PANSS, CDSS and CGI scales. Conclusion: In our study, L-arginine did not seem to have an effect on schizophrenia symptoms. Studies with a larger sample size, with higher doses of L-arginine, and with a longer duration are needed for a definite conclusion.
- 1 June 2016
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 36 (3) , 257-261
Relation of the Allelic Variants of Multidrug Resistance Gene to Agranulocytosis Associated With Clozapine
Clozapine use is associated with leukopenia and more rarely agranulocytosis, which may be lethal. The drug and its metabolites are proposed to interact with the multidrug resistance transporter (ABCB1/MDR1) gene product, P-glycoprotein (P-gp). Among various P-glycoprotein genetic polymorphisms, nucleotide changes in exons 26 (C3435T), 21 (G2677T), and 12 (C1236T) have been implicated for changes in pharmacokinetics and pharmacodynamics of many substrate drugs. In this study, we aimed to investigate the association between these specific ABCB1 polymorphisms and clozapine-associated agranulocytosis (CAA). Ten patients with a history of CAA and 91 control patients without a history of CAA, despite 10 years of continuous clozapine use, were included. Patient recruitment and blood sample collection were conducted at the Hacettepe University Faculty of Medicine, Department of Psychiatry, in collaboration with the members of the Schizophrenia and Other Psychotic Disorders Section of the Psychiatric Association of Turkey, working in various psychiatry clinics. After DNA extraction from peripheral blood lymphocytes, genotyping was performed using polymerase chain reaction and endonuclease digestion. Patients with CAA had shorter duration of clozapine use but did not show any significant difference in other clinical, sociodemographic characteristics and in genotypic or allelic distributions of ABCB1 variants and haplotypes compared with control patients. Among the 10 patients with CAA, none carried the ABCB1 all-variant haplotype (TT-TT-TT), whereas the frequency of this haplotype was approximately 12% among the controls. Larger sample size studies and thorough genetic analyses may reveal both genetic risk and protective factors for this serious adverse event.
- 1 June 2016
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 36 (3) , 257-261
Relation of the Allelic Variants of Multidrug Resistance Gene to Agranulocytosis Associated With Clozapine
Clozapine use is associated with leukopenia and more rarely agranulocytosis, which may be lethal. The drug and its metabolites are proposed to interact with the multidrug resistance transporter (ABCB1/MDR1) gene product, P-glycoprotein (P-gp). Among various P-glycoprotein genetic polymorphisms, nucleotide changes in exons 26 (C3435T), 21 (G2677T), and 12 (C1236T) have been implicated for changes in pharmacokinetics and pharmacodynamics of many substrate drugs. In this study, we aimed to investigate the association between these specific ABCB1 polymorphisms and clozapine-associated agranulocytosis (CAA). Ten patients with a history of CAA and 91 control patients without a history of CAA, despite 10 years of continuous clozapine use, were included. Patient recruitment and blood sample collection were conducted at the Hacettepe University Faculty of Medicine, Department of Psychiatry, in collaboration with the members of the Schizophrenia and Other Psychotic Disorders Section of the Psychiatric Association of Turkey, working in various psychiatry clinics. After DNA extraction from peripheral blood lymphocytes, genotyping was performed using polymerase chain reaction and endonuclease digestion. Patients with CAA had shorter duration of clozapine use but did not show any significant difference in other clinical, sociodemographic characteristics and in genotypic or allelic distributions of ABCB1 variants and haplotypes compared with control patients. Among the 10 patients with CAA, none carried the ABCB1 all-variant haplotype (TT-TT-TT), whereas the frequency of this haplotype was approximately 12% among the controls. Larger sample size studies and thorough genetic analyses may reveal both genetic risk and protective factors for this serious adverse event.